Compare Stocks: EWTX, ASND, HALO, and BBIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$256.82 +1.3%	$242.50	$188.07 ▼ $282.15	$15.53B	0.4	679,756 shs	883,782 shs
BBIO BridgeBio Pharma	$74.29 +0.0%	$69.76	$60.55 ▼ $93.42	$14.61B	0.97	2.85 million shs	3.16 million shs
EWTX Edgewise Therapeutics	$45.04 +15.9%	$40.86	$16.70 ▼ $48.51	$4.14B	0.39	1.35 million shs	3.71 million shs
HALO Halozyme Therapeutics	$103.63 -15.7%	$115.19	$61.22 ▼ $134.00	$14.64B	0.92	2.19 million shs	6.16 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+1.33%	+2.21%	+12.44%	+0.55%	+29.87%
BBIO BridgeBio Pharma	+0.03%	-0.88%	+11.71%	-12.06%	+18.56%
EWTX Edgewise Therapeutics	+15.87%	+15.59%	+13.82%	+3.49%	+159.30%
HALO Halozyme Therapeutics	-15.72%	-20.84%	-6.46%	+0.49%	+51.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$256.82 +1.3%	$242.50	$188.07 ▼ $282.15	$15.53B	0.4	679,756 shs	883,782 shs
BBIO BridgeBio Pharma	$74.29 +0.0%	$69.76	$60.55 ▼ $93.42	$14.61B	0.97	2.85 million shs	3.16 million shs
EWTX Edgewise Therapeutics	$45.04 +15.9%	$40.86	$16.70 ▼ $48.51	$4.14B	0.39	1.35 million shs	3.71 million shs
HALO Halozyme Therapeutics	$103.63 -15.7%	$115.19	$61.22 ▼ $134.00	$14.64B	0.92	2.19 million shs	6.16 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+1.33%	+2.21%	+12.44%	+0.55%	+29.87%
BBIO BridgeBio Pharma	+0.03%	-0.88%	+11.71%	-12.06%	+18.56%
EWTX Edgewise Therapeutics	+15.87%	+15.59%	+13.82%	+3.49%	+159.30%
HALO Halozyme Therapeutics	-15.72%	-20.84%	-6.46%	+0.49%	+51.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	2.90	Moderate Buy	$305.95	19.13% Upside
BBIO BridgeBio Pharma	2.82	Moderate Buy	$104.26	40.35% Upside
EWTX Edgewise Therapeutics	2.58	Moderate Buy	$52.83	17.30% Upside
HALO Halozyme Therapeutics	2.77	Moderate Buy	$106.09	2.37% Upside

Current Analyst Ratings Breakdown

Latest EWTX, ASND, HALO, and BBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/6/2026	HALO Halozyme Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Outperform	$93.00 ➝ $149.00
11/6/2026	HALO Halozyme Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Equal Weight	$95.00 ➝ $110.00
11/5/2026	EWTX Edgewise Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Underperform	$85.00
11/5/2026	EWTX Edgewise Therapeutics	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$53.00 ➝ $51.00
11/3/2026	HALO Halozyme Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Neutral	$78.00 ➝ $79.00
11/2/2026	BBIO BridgeBio Pharma	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$106.00 ➝ $108.00
10/30/2026	BBIO BridgeBio Pharma	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/30/2026	BBIO BridgeBio Pharma	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$110.00 ➝ $100.00
10/30/2026	BBIO BridgeBio Pharma	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$87.00 ➝ $88.00
10/26/2026	ASND Ascendis Pharma A/S	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$268.00
10/26/2026	ASND Ascendis Pharma A/S	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$360.00 ➝ $330.00

(Data available from 11/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	19.67	N/A	N/A	($2.97) per share	-86.47
BBIO BridgeBio Pharma	$502.08M	28.82	N/A	N/A	($13.32) per share	-5.58
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	$4.93 per share	N/A
HALO Halozyme Therapeutics	$1.40B	8.42	$3.83 per share	27.03	$0.42 per share	246.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	19.92	28.86	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
BBIO BridgeBio Pharma	-$724.93M	-$3.04	N/A	N/A	N/A	-59.84%	N/A	-39.81%	N/A
EWTX Edgewise Therapeutics	-$167.79M	$8.19	5.50	N/A	N/A	N/A	-39.01%	-36.96%	N/A
HALO Halozyme Therapeutics	$316.89M	$3.93	26.37	10.56	0.49	24.86%	260.98%	23.91%	N/A

Latest EWTX, ASND, HALO, and BBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/11/2026	Q3 2026	ASND Ascendis Pharma A/S	$0.8940	N/A	N/A	N/A	$409.40 million	N/A
11/5/2026	Q3 2026	HALO Halozyme Therapeutics	$2.30	$2.39	+$0.09	$2.01	$491.63 million	$492.97 million
11/4/2026	Q3 2026	EWTX Edgewise Therapeutics	-$0.5316	$9.65	+$10.1816	$9.65	$119.23 million	N/A
10/29/2026	Q3 2026	BBIO BridgeBio Pharma	-$0.5423	-$0.42	+$0.1223	-$0.42	$293.47 million	$353.17 million
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/10/2026	Q2 2026	BBIO BridgeBio Pharma	-$0.5756	-$0.78	-$0.2044	-$0.78	$220.91 million	$243.68 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
EWTX Edgewise Therapeutics	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
BBIO BridgeBio Pharma	N/A	2.09	2.03
EWTX Edgewise Therapeutics	N/A	16.24	16.24
HALO Halozyme Therapeutics	13.50	2.71	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
BBIO BridgeBio Pharma	99.85%
EWTX Edgewise Therapeutics	N/A
HALO Halozyme Therapeutics	97.79%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
BBIO BridgeBio Pharma	14.23%
EWTX Edgewise Therapeutics	21.30%
HALO Halozyme Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
BBIO BridgeBio Pharma	839	194.80 million	167.08 million	Optionable
EWTX Edgewise Therapeutics	127	108.60 million	85.47 million	Optionable
HALO Halozyme Therapeutics	423	113.50 million	110.66 million	Optionable

EWTX, ASND, HALO, and BBIO Headlines

Recent News About These Companies

Halozyme Therapeutics (NASDAQ:HALO) Share Price Breaks Below 50 Day Moving Average - Here's Why

November 7 at 8:18 AM | marketbeat.com

Halozyme Therapeutics (NASDAQ:HALO) Rating Lowered to "Buy" at Wall Street Zen

November 7 at 7:51 AM | marketbeat.com

Halozyme (HALO) Receives a Buy from H.C. Wainwright

November 6 at 9:46 PM | theglobeandmail.com

Stock Market Movers: Biggest Gainers and Losers on 6 November 2026

November 6 at 5:11 PM | insidermonkey.com

Halozyme Dips on Royalty Statement

November 6 at 4:46 PM | baystreet.ca

Halozyme sees minimal royalty revenue impact from Medicare pricing rule

November 6 at 4:46 PM | streetinsider.com

Halozyme Therapeutics, Inc.: U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE Technology for the Treatment of ...

November 6 at 4:46 PM | finanznachrichten.de

Halozyme dips as Leerink downgrades on “marginal” Q3 upside

November 6 at 4:46 PM | seekingalpha.com

Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still Undervalued

November 6 at 4:46 PM | finance.yahoo.com

Halozyme Stock Down Despite Q3 Earnings and Revenue Beat

November 6 at 1:01 PM | zacks.com

Halozyme Therapeutics (NASDAQ:HALO) Stock Falls 11.5% - What's Next?

November 6 at 11:59 AM | marketbeat.com

Halozyme Stock Jumps On Strong Earnings But Guidance Reset Raises Questions

November 6 at 11:45 AM | uk.finance.yahoo.com

HALO Q3 Earnings Call Highlights Royalty Growth and Patent Dispute

November 6 at 11:01 AM | zacks.com

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Expected to Rise, Citizens Jmp Analyst Says

November 6 at 10:29 AM | marketbeat.com

Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

November 6 at 10:04 AM | prnewswire.com

U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with Halozyme's ENHANZE® Technology for the Treatment of Advanced Head and Neck Cancer

November 6 at 9:57 AM | prnewswire.com

Halozyme Therapeutics (NASDAQ:HALO) Stock Price Target Raised at Wells Fargo & Company

November 6 at 9:47 AM | marketbeat.com

What Halozyme Therapeutics (HALO) Said on Its Q3 Earnings Call

November 5 at 12:13 AM | marketbeat.com

Halozyme Therapeutics (NASDAQ:HALO) Releases Earnings Results, Beats Expectations By $0.09 EPS

November 5 at 11:55 PM | marketbeat.com

Halozyme Q3 2026: Record Royalties Drive a Guidance Raise

November 5 at 8:30 PM | 247wallst.com

Halozyme Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 5 at 8:30 PM | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EWTX, ASND, HALO, and BBIO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$256.82 +3.37 (+1.33%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$257.75 +0.93 (+0.36%)

As of 11/6/2026 07:34 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma NASDAQ:BBIO

$74.29 +0.02 (+0.03%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$74.26 -0.03 (-0.04%)

As of 11/6/2026 07:30 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Edgewise Therapeutics NASDAQ:EWTX

$45.04 +6.17 (+15.87%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$45.40 +0.36 (+0.80%)

As of 11/6/2026 07:30 PM Eastern

Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Halozyme Therapeutics NASDAQ:HALO

$103.63 -19.33 (-15.72%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$104.48 +0.84 (+0.82%)

As of 11/6/2026 07:45 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EWTX, ASND, HALO, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EWTX, ASND, HALO, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EWTX, ASND, HALO, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EWTX, ASND, HALO, and BBIO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Edgewise Therapeutics NASDAQ:EWTX

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest EWTX, ASND, HALO, and BBIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest EWTX, ASND, HALO, and BBIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

EWTX, ASND, HALO, and BBIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

EWTX, ASND, HALO, and BBIO Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

BridgeBio Pharma NASDAQ:BBIO

Edgewise Therapeutics NASDAQ:EWTX

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools